Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Sarepta Therapeutics Inc. Is Down Today

By Brian Feroldi - Feb 8, 2016 at 4:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of a pushback in its PDUFA date sends shares lower.

What: Shares of clinical-stage Sarepta Therapeutics ( SPRT ) dropped more than 11% as of 3:30 p.m. ET after the company received news that its PDUFA decision date has been extended.

So what: The Food and Drug Administration informed Sarepta today that it needed more time to review its New Drug Application for eteplirsen, its potential treatment for Duchenne muscular dystrophy, or DMD. The FDA pushed its decision date back three months and now expects to have an answer by May 26, 2016.

The reason for the delayed decision date can be traced back to additional clinical data that Sarepta handed to the FDA on Jan. 8. That data has been designated by the FDA as a major amendment to the company's NDA submission, and the FDA is demanding an additional three months' time to review the additional data. 

News of having to wait an additional 90 days to hear a decision has put the market in a foul mood, hence why shares are falling. 

Now what: Sarepta Therapeutics' shares have been a basket case for months now as eteplirsen's original PDUFA date has drawn closer. Investors were initially excited about its chances for gaining approval, especially after a competing DMD drug from BioMarin Pharmaceutical ( BMRN 1.55% ) called Kyndrisa received some harsh words at its FDA advisory committee meeting. That seemed to tilt the likelihood of approval in Sarepta's favor, especially since eteplirsen had already been granted priority review and fast-track status. 

However, in January, an FDA advisory committee report raised some serious concerns about Sarepta's eteplirsen, calling into question how efficacious the drug really is and the methodology that the company used to collect data in its clinical trial. Shares of Sarepta tanked after the report was released.

It now looks like we won't have a definitive answer either way until May. There's not much that investors can do between now and then but wait and hope for the best.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned, Inc. Stock Quote, Inc.
BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
$84.24 (1.55%) $1.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.